TernsPharmaceuticals News & Analysis
2 articles
Market Mood
Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Barclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.
Read More
Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals
Merck has announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion. This acquisition is seen as part of Merck's strategy to expand its oncology portfolio and strengthen its pipeline. The deal aligns with Merck's focus on innovative drug development. The transaction is expected to close in the fourth quarter of 2023, pending regulatory approvals.
Read More